25 Spam-Free Article(s) Found
Article Searches
Merck's Keytruda Receives Priority Review for a Key Indication https://www.fool.com/investing/2020/04/07/mercks-keytruda-receives-priority-review-for-a-key.aspx?source=iedfolrf0000001 Apr 07, 2020 - An approval would give the immunotherapy another big leg up on Bristol Myers Squibb's similar treatment Opdivo.
3 Safe Dividend Stocks to Buy Right Now https://www.fool.com/investing/2020/04/12/3-safe-dividend-stocks-to-buy-right-now.aspx?source=iedfolrf0000001 Apr 12, 2020 - Companies are cutting and suspending dividend stocks all over the place. These payouts are not at risk.
Merck & Co Inc (MRK) Q1 2020 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2020/04/28/merck-co-inc-mrk-q1-2020-earnings-call-transcript.aspx?source=iedfolrf0000001 Apr 28, 2020 - MRK earnings call for the period ending March 31, 2020.
Merck & Co., Inc. (MRK) CEO Ken Frazier on Q1 2020 Results - Earnings Call Transcript https://seekingalpha.com/article/4340675-merck-co-inc-mrk-ceo-ken-frazier-on-q1-2020-results-earnings-call-transcript?source=feed_sector_healthcare Apr 28, 2020 - Merck & Co., Inc. (NYSE:MRK) Q1 2020 Results Earnings Conference Call April 28, 2020 08:00 AM ET Company Participants Peter Dannenbaum - Vice President, Investor Relations Ken Frazier - Chairman a
Why Merck (MRK) is a Top Dividend Stock for Your Portfolio http://www.zacks.com/stock/news/845194/why-merck-mrk-is-a-top-dividend-stock-for-your-portfolio?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-845194 Mar 30, 2020 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
AstraZeneca's Imfinzi Gets FDA Nod for SCLC Label Expansion http://www.zacks.com/stock/news/845152/astrazenecas-imfinzi-gets-fda-nod-for-sclc-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-845152 Mar 30, 2020 - AstraZeneca's (AZN) Imfinzi gets FDA approval as first-line treatment for extensive-stage small cell lung cancer patients. A phase III study on Farxiga in CKD patients meets endpoint earlier than expected.
3 Stocks Immune to the Coronavirus Downturn to Buy Right Now http://www.zacks.com/stock/news/857564/3-stocks-immune-to-the-coronavirus-downturn-to-buy-right-now?cid=CS-ZC-FT-zacks_friday_finish_line-857564 Apr 06, 2020 - Today's episode of Full Court Finance here at Zacks quickly dives into why Wall Street seems optimistic on Monday. Despite the positivity, investors should still be on the hunt for stocks that appear immune to the broader coronavirus fallout...
The Zacks Analyst Blog Highlights: Johnson & Johnson, Merck & Co, Novartis, PayPal and IBM http://www.zacks.com/stock/news/858931/the-zacks-analyst-blog-highlights-johnson-johnson-merck-co-novartis-paypal-and-ibm?cid=CS-ZC-FT-press_releases-858931 Apr 07, 2020 - The Zacks Analyst Blog Highlights: Johnson & Johnson, Merck & Co, Novartis, PayPal and IBM
Immunomedics' Sacituzumab Govitecan Gets Fast Track Tag for UC http://www.zacks.com/stock/news/861178/immunomedics-sacituzumab-govitecan-gets-fast-track-tag-for-uc?cid=CS-ZC-FT-analyst_blog|industry_focus-861178 Apr 08, 2020 - The FDA bestows a fast track status on Immunomedics' (IMMU) sacituzumab govitecan for treating adult patients with locally advanced or metastatic urothelial cancer (mUC).
Merck's Keytruda Gets FDA's Priority Review for Solid Tumors http://www.zacks.com/stock/news/861111/mercks-keytruda-gets-fdas-priority-review-for-solid-tumors?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-861111 Apr 08, 2020 - Merck's (MRK) sBLA seeking approval of Keytruda for advanced solid tumors, based on biomarker, regardless of tumor type, gets FDA's priority review.

Pages: 123

Page 1>